59084-06-9

Usage

Chemical Properties

Yellow solid

InChI:InChI=1/C10H13N3O2/c14-13(15)10-4-2-1-3-9(10)12-7-5-11-6-8-12/h1-4,11H,5-8H2/p+1

Upstream product

• 110-85-0 piperazine 
• 88-73-3 2-Chloronitrobenzene 
• 577-19-5 2-nitrophenyl bromide 
• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 
• 88-74-4 2-nitro-aniline 
• 1493-27-2 ortho-nitrofluorobenzene 
• 170017-73-9 1-[1,1-Dimethylethoxycarbonyl]-4-(2-nitrophenyl)piperazine 

Downstream Products

• 134390-56-0 2-{4-[4-(2-Nitro-phenyl)-piperazin-1-yl]-butyl}-isoindole-1,3-dione 
• 74760-12-6 1-(3,4,5-trimethoxyphenoxy)-3-<4-(2-nitrophenyl)piperazinyl>propan-2-ol 
• 203395-88-4 7-{4-[4-(2-Nitro-phenyl)-piperazin-1-yl]-butoxy}-3,4-dihydro-1H-quinolin-2-one 
• 199105-16-3 1-benzyl-4-(2-nitrophenyl)piperazine 
• 170017-73-9 1-[1,1-Dimethylethoxycarbonyl]-4-(2-nitrophenyl)piperazine 
• 444583-81-7 1-(N-tert-butoxycarbonyl-D-Tic-4-Cl-D-Phe)-4-(2-nitrophenyl)piperazine 
• 630116-10-8 N-(3-methylphenyl)-2-[4-(2-nitrophenyl)-1-piperazinyl]acetamide 
• 13339-02-1 1-(2-aminophenyl)piperazine 
• 4744-53-0 NSC 700996 
• 115213-55-3 2-methyl-1,2,3,4-tetrahydro-benz[4,5]imidazo[1,2-a]pyrazine 
• 91646-45-6 1-(4-(2-aminophenyl)piperazin-1-yl)ethanone 
• 91703-27-4 5-[4-(2-nitrophenyl)piperazin-1-yl]pyrrolidin-2-one 
• 1253383-30-0 2-(3,5-dimethyl-pyrazol-1-yl)-1-[4-(2-nitro-phenyl)-piperazin-1-yl]-ethanone 

Relevant academic research and scientific papers

Synthesis and structure-activity relationships of new 2-phenoxybenzamides with antiplasmodial activity

The 2-phenoxybenzamide 1 from the Medicines for Malaria Venture Malaria Box Project has shown promising multi-stage activity against different strains of P. falciparum. It was successfully synthesized via a retrosynthetic approach. Subsequently, twenty-one new derivatives were prepared and tested for their in vitro activity against blood stages of the NF54 strain of P. falciparum. Several insights into structure-activity relationships were revealed. The antiplasmodial activity and cytotoxicity of compounds strongly depended on the substitution pattern of the anilino partial structure as well as on the size of substituents. The diaryl ether partial structure had further impacts on the activity. Additionally, several physicochemical and pharmacokinetic parameters were calculated (log P, log D7.4 and ligand efficiency) or determined experimentally (passive permeability and CYP3A4 inhibition). The tert-butyl-4-{4-[2-(4-fluorophenoxy)-3-(trifluoromethyl)benzamido]phenyl}piperazine-1-carboxylate possesses high antiplasmodial activity against P. falciparum NF54 (PfNF54 IC50 = 0.2690 μM) and very low cytotoxicity (L-6 cells IC50 = 124.0 μM) resulting in an excellent selectivity index of 460. Compared to the lead structure 1 the antiplasmodial activity was improved as well as the physicochemical and some pharmacokinetic parameters.

Preparation method of high-purity vortioxetine hydrobromide

The invention belongs to the field of chemistry, and particularly relates to a preparation method of high-purity vortioxetine hydrobromide. According to the preparation method for preparing the high-purity vortioxetine hydrobromide, the o-fluoronitrobenzene and the piperazine are used as starting raw materials, the vortioxetine hydrobromide is further prepared in the organic solvent, the raw materials used in the method are low in price and cost and easy to operate, and the prepared vortioxetine hydrobromide is high in purity and few in impurity.

REGULATOR OF NITROGEN-CONTAINING HETEROAROMATIC DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF

The present invention relates to a regulator of nitrogen-containing heteroaromatic derivatives, a preparation method therefor and the use thereof. In particular, the present invention relates to a compound as shown in the general formula (I), a preparation method therefor and a pharmaceutical composition containing the compound, and the use thereof as a protein tyrosine phosphatase-2C (SHP2) inhibitor in the treatment of diseases or conditions such as leukemia, neuroblastoma, melanoma, breast cancer, lung cancer and colorectal cancer, wherein the definition of each substituent in the general formula (I) is the same as that in the description.

PROCESS AND NOVEL POLYMORPHIC FORM OF VORTIOXETINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS

Processes are disclosed for making vortioxetine and pharmaceutically acceptable salts thereof. A propylene glycol solvate of vortioxetine hydrobromide is disclosed. A novel crystalline form of vortioxetine hydrobromide propylene glycol solvate, designated form AC1, is disclosed along with a method for making same. Form AC1 may be characterized by an x-ray powder diffraction pattern with peaks at about 19.64, 22.85, 25.51, 29.57, 30.18±0.2 degrees 2-theta.

PYRROLE mTORC INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

PYRROLE mTORC INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

INTERMEDIATES AND PROCESSES FOR PREPARATION OF VORTIOXETINE

The present invention relates to new intermediate compounds useful in the preparation of phenyl-piperazine compounds such as Vortioxetine and process for their preparation. The present invention also relates to process for preparing Vortioxetine or its pharmaceutically acceptable salts using said intermediates.

Chrysin-piperazine conjugates as antioxidant and anticancer agents

Synthesis of 7-(4-bromobutoxy)-5-hydroxy-2-phenyl-4H-chromen-4-one intermediate treating chrysin with 1,4-dibromobutane facilitated combination of chrysin with a wide range of piperazine moieties which were equipped via reacting the corresponding amines with bis(2-chloroethyl)amine hydrochloride in diethylene glycol monomethyl ether solvent. Free radical scavenging potential of prepared products was analyzed in vitro adopting DPPH and ABTS bioassay in addition to the evaluation of in vitro anticancer efficacies against cervical cancer cell lines (HeLa and CaSki) and an ovarian cancer cell line SK-OV-3 using SRB assay. Bearable toxicity of 7a-w was examined employing Madin-Darby canine kidney (MDCK) cell line. In addition, cytotoxic nature of the presented compounds was inspected utilizing Human bone marrow derived mesenchymal stem cells (hBM-MSCs). Overall, 7a-w indicated remarkable antioxidant power in scavenging DPPH+ and ABTS++, particularly analogs 7f, 7j, 7k, 7l, 7n, 7q, 7v, 7w have shown promising free radical scavenging activity. Analogs 7j and 7o are identified to be highly active candidates against HeLa and CaSki cell lines, whereas 7h and 7l along with 7j proved to be very sensitive towards ovarian cancer cell line SKOV-3. None of the newly prepared scaffolds showed cytotoxic nature toward hBM-MSCs cells. From the structure-activity point of view, nature and position of the electron withdrawing and electron donating functional groups on the piperazine core may contribute to the anticipated antioxidant and anticancer action. Different spectroscopic techniques (FT-IR, 1H NMR, 13C NMR, Mass) and elemental analysis (CHN) were utilized to confirm the desired structure of final compounds.

SYNTHESIS OF VORTIOXETINE VIA (2-(PIPERAZINE-1 -YL)PHENYL)ANILINE INTERMEDIATES

The present invention provides a new synthetic process for the production of 1-(2-((2,4- dimethylphenyl)thio)phenyl)piperazine (vortioxetine), a drug for the treatment of depression and anxiety, which is conducted via (2-(piperazine-1-yl)phenyl)aniline intermediates.

Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)aniline intermediates

The present invention provides a new synthetic process for the production of 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine (vortioxetine), a drug for the treatment of depression and anxiety, which is conducted via (2-(piperazine-1-yl)phenyl)aniline intermediates.